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Summary  Primary  percutaneous  coronary  intervention  (PCI)  is  the  best  available  reperfusion
strategy  for  acute  ST-segment  elevation  myocardial  infarction  (STEMI),  with  nearly  95%  of
occluded  coronary  vessels  being  reopened  in  this  setting.  Despite  re-establishing  epicardial
coronary vessel  patency,  primary  PCI  may  fail  to  restore  optimal  myocardial  reperfusion  within
the myocardial  tissue,  a  failure  at  the  microvascular  level  known  as  no-reﬂow  (NR).  NR  has  been
reported to  occur  in  up  to  60%  of  STEMI  patients  with  optimal  coronary  vessel  reperfusion.  When
it does  occur,  it  signiﬁcantly  attenuates  the  beneﬁcial  effect  of  reperfusion  therapy,  leading
to poor  outcomes.  The  pathophysiology  of  NR  is  complex  and  incompletely  understood.  Many
phenomena  are  known  to  contribute  to  NR,  including  leukocyte  inﬁltration,  vasoconstriction,
activation  of  inﬂammatory  pathways  and  cellular  oedema.  Vascular  damage  and  haemorrhage
may also  play  important  roles  in  the  establishment  of  NR.  In  this  review,  we  describe  the  patho-
physiological  mechanisms  of  NR  and  the  tools  available  for  diagnosing  it.  We  also  describe  the
Abbreviations: AMI, acute myocardial infarction; ANGPTL4, angiopoietin-like 4; ATP, adenosine triphosphate; CMR, cardiac magnetic
resonance; ce-CMR, contrast-enhanced cardiac magnetic resonance; IV, intravenous; MBG, myocardial blush grade; MVO, microvascular
obstruction; NR, no-reﬂow; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; TIMI, thrombolysis
in myocardial infarction; VE, vascular endothelial; VEGF, vascular endothelial growth factor.
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microvasculature  and  the  endothelial  mechanisms  involved  in  NR,  which  may  provide  relevant
therapeutic  targets  for  reducing  NR  and  improving  the  prognosis  for  patients.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’angioplastie  coronaire  primaire  en  urgence  est  la  méthode  de  choix  de  reper-
fusion coronarienne  pour  les  patients  présentant  un  infarctus  du  myocarde.  Le  taux  de  succès
angiographique  de  l’angioplastie  coronaire  est  actuellement  de  95  %.  Cependant,  malgré  la
restauration  du  ﬂux  épicardique,  l’angioplastie  peut  ne  pas  entraîner  de  reperfusion  réelle-
ment efﬁcace  du  tissue  myocardique  profond.  Ce  défaut  de  reperfusion  de  la  microcirculation
myocardique  correspond  au  phénomène  de  no-reﬂow.  Selon  les  études,  celui-ci  est  retrouvé
chez 10  à  60  %  des  patients  ayant  pourtant  bénéﬁcié  d’une  reperfusion  angiographique  opti-
male. Le  no-reﬂow  atténue  le  bénéﬁce  de  la  reperfusion  et  est  un  facteur  de  mauvais  pronostic
clinique  à  la  phase  aiguë  et  à  long  terme  avec  alteration  de  la  fraction  d’éjection  ventriculaire
gauche, insufﬁsance  cardiaque  clinique  et  survenue  d’événements  rythmiques  ventriculaires.
La physiopathologie  du  no-reﬂow  et  sa  cinétique  sont  complexes  et  mal  comprises.  Plus  que
l’embolisation  distale  de  débris  athéro-thrombotiques,  de  nombreux  phénomènes  tels  que  la
vasoconstriction,  l’œdème  intra-  et  extra-cellulaire,  l’inﬂammation  avec  inﬁltration  leucocy-
taire et  libération  de  signaux  cytotoxiques,  participent  au  no-reﬂow.  De  plus,  des  données
récentes démontrent  un  rôle  important  des  dommages  endothéliaux  et  de  l’hémorragie  intra-
myocardique.  La  perte  d’integrité  de  la  barrière  endothéliale  lors  de  la  reperfusion  brutale
du myocarde  ischémié  entraîne  une  hyperperméabilité  vasculaire  qui  semble  être  un  acteur
majeur du  no-reﬂow.  Dans  cette  revue,  nous  analyserons  les  mécanismes  physiopathologiques
impliqués  dans  le  no-reﬂow,  nous  décrirons  les  outils  diagnostiques  disponibles,  les  éléments
du pronostic  et  les  différentes  thérapeutiques  à  l’essai.  Nous  porterons  une  attention  parti-
culière à  la  protection  de  l’endothélium  microvasculaire,  qui  pourrait  constituer  une  nouvelle
cible thérapeutique  pour  diminuer  le  no-reﬂow.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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cackground
rimary  percutaneous  coronary  intervention  (PCI)  is  the  best
vailable  reperfusion  strategy  in  patients  with  acute  ST-
egment  elevation  myocardial  infarction  (STEMI)  [1].  Up  to
5%  of  occluded  coronary  vessels  can  be  reopened  in  the
etting  of  STEMI  [2—5].  However,  despite  re-establishing
he  epicardial  coronary  vessel  patency,  primary  PCI  may
ail  to  restore  optimal  myocardial  reperfusion  within  the
yocardial  tissue  in  patients  with  STEMI.  This  reperfusion
ailure  at  the  microvascular  level  is  a  condition  known  as
o-reﬂow  (NR)  [6—10].  NR  has  been  described  in  up  to
0%  of  STEMI  patients  with  optimal  coronary  vessel  reper-
usion  [3,11—19].  When  NR  occurs,  it  signiﬁcantly  attenuates
he  beneﬁcial  impact  of  reperfusion  therapy,  resulting  in
oor  clinical  and  functional  outcomes  [6,20—22].  But  do
e  really  know  what  the  NR  phenomenon  is?  The  patho-
hysiology  of  NR  is  complex  and  is  not  fully  understood;
t  involves  much  more  than  just  distal  embolization  of
hrombotic  debris.  Indeed,  many  phenomena  contribute  to
R:  leukocyte  inﬁltration,  vasoconstriction,  activation  of
nﬂammatory  pathways  and  cellular  oedema  [23,24]  (Fig.  1).
ecently,  experimental  data  demonstrated  the  important
oles  played  by  vascular  damage  and  haemorrhage  in  the
stablishment  of  NR.  Vascular  permeability  at  the  endothe-
ial  level  appears  to  be  a  major  factor  in  NR.
l
o
cIn  this  state-of-the-art  review,  we  will  cover  all  the
escribed  pathophysiological  mechanisms  and  the  tools
vailable  for  diagnosing  NR  in  clinical  settings.  We  will  also
ocus  further  on  the  microvasculature  and  the  endothelial
echanisms  involved  in  NR,  which  may  provide  relevant
herapeutic  targets  to  reduce  NR  and  improve  patient  prog-
osis.
athophysiological mechanisms and
redictive factors
he  NR  phenomenon  was  described  for  the  ﬁrst  time  by
loner  et  al.  in  1974  [25],  in  a  canine  experimental  model
f  myocardial  ischaemia-reperfusion.
schaemia injury
R  starts  with  the  initial  severe  ischaemic  insult.
ethal  ischaemia,  deﬁned  by  a  myocardial  tissue  blood
ow  <  40  mL/min  for  100  g  of  tissue,  causes  irreversible
ardiomyocyte  and  endothelial  damage.  At  the  endothe-
ial  level,  bleb  formation  and  endothelial  protrusion  are
bserved,  and  obstruct  the  microcirculation.  Endothelial
ell  necrosis  leads  to  destruction  of  tight  and  adherens
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Figure 1. No-reﬂow pathophysiology. No-reﬂow or microvascular obstruction/reperfusion injury is a dynamic and complex phenomenon
that starts with lethal ischaemia and ends ultimately with replacement of the injured myocardial tissue with a dense ﬁbrotic scar. The
phenomenon takes its seeds in a prolonged (>30 minutes) lethal ischaemia to the healthy myocardium, resulting in cell death. The second
phase is caused by the brutal reperfusion of the ischaemic myocardium. In the following 24 hours, a cascade of deleterious phenomena
take place, including intra- and extracellular oedema, microvessel obstruction with atherothrombotic material as well as cell debris,
vasoconstriction induced by platelet hyperactivation and important cytotoxic signals delivered by the different myocardial cell components.
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tAfter 24 hours, an important inﬂammatory response in the ischaemi
occurs and can cause additional damage to the myocardium.
junctions  and  loss  of  vascular  integrity,  which,  in  turn,
leads  to  extravascular  accumulation  of  ﬂuid  and  blood
cells  [26].  This  extravascular  expansion  provokes  vascu-
lar  compression  and  a  reduction  in  the  microvessel  lumen.
Also,  endothelial  nitric  oxide  production  is  altered,  and
impairs  the  endothelium-dependent  vasodilatation.  At  the
cardiomyocyte  level,  ischaemia  causes  cell  necrosis  and
cardiomyocyte  swelling,  which  increases  compression  of
intramural  vessels  [26,27].
Reperfusion injury
The  ischaemia-related  injury  is  made  worse  by  reperfusion
injury.  Reperfusion  injury,  caused  by  the  brutal  restora-
tion  of  a  normal  blood  supply  (100  mL/min  for  100  g)  to
damaged  microvessels,  accelerates  myocardial  swelling,  tis-
sue  oedema,  endothelial  disruption  and  inﬂammation  [28].
The  production  of  oxygen-free  radicals  is  enhanced  by  this
w
b
I
hred myocardium as well as the non-infarcted remote myocardium
eperfusion  within  the  ﬁrst  few  minutes  of  reﬂow  and  also
akes  part  in  reperfusion  injury  [29].
Neutrophils  and  platelets  form  microaggregates  (plugs),
hich  are  responsible  for  luminal  obstruction  of  the
icrovasculature  [30,31]. Autonomic  dysfunction  also
ccurs  upon  reperfusion,  with  alpha-adrenergic  receptor-
ediated  constriction  of  coronary  microvessels,  which  may
ontribute  to  NR  [32].
nfarct size
everal  studies  have  demonstrated  a correlation  between
arger  infarct  size  and  NR,  in  terms  of  both  frequency
nd  importance  [33—36]. As  necrosis  is  associated  with
issue  destruction,  oedema  and  mechanical  compression,
hich  are  pathophysiological  factors  in  NR,  the  association
etween  infarct  size  and  NR  has  been  demonstrated  [27].
n  line  with  this  interpretation,  a  higher  incidence  of  NR
as  been  reported  when  the  culprit  vessel  is  the  proximal
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eft  anterior  descending  coronary  artery  responsible  for  the
argest  myocardial  infarction  [36—38].  Similarly,  longer  pain-
o-balloon  time  is  related  to  the  development  of  NR,  as  it  is
inked  to  a  larger  infarct  area  [36,39].
ndothelial injury
 major  regulator  of  endothelial  integrity  is  vascular
ndothelial  growth  factor  (VEGF),  which  was  originally
alled  vascular  permeability  factor  [40].  VEGF  is  expressed
n  response  to  hypoxia  during  acute  myocardial  infarc-
ion  (AMI)  [41—46].  In  a  resting  state,  VEGF  receptor  2
orms  a  complex  with  vascular  endothelial  (VE)-cadherin,  an
ndothelial-speciﬁc  adhesion  protein  that  stabilizes  inter-
ellular  adherens  junctions  [47].  Ischaemia-induced  VEGF,
hen  binding  to  VEGF  receptor  2,  dissociates  the  VEGF
eceptor  2/VE-cadherin  complex,  leading  to  an  increase
n  endothelial  permeability  [48].  VEGF  activates  Src  phos-
horylation,  which  then  induces  tyrosine  phosphorylation  of
E-cadherin  and  its  internalization;  this  reduces  the  amount
f  VE-cadherin  available  at  interendothelial  junctions,  thus
eading  to  disruption  of  endothelial  barrier  integrity.  In
ivo,  VE-cadherin  phosphorylation  is  also  modulated  by  the
aemodynamic  forces  and  shear  stress  to  which  endothe-
ial  cells  are  exposed  [49].  So,  driven  by  its  phosphorylation
tate,  VE-cadherin  plays  a  major  role  in  maintaining  strong
nterendothelial  junctions.  In  experimental  models,  vas-
ular  permeability  plays  a  central  role  in  NR.  However
here  are  few  data  from  human  patients  on  the  basal  and
schaemia-induced  phosphorylation  levels  of  VE-cadherin  in
he  coronary  microcirculation,  which  might  represent  a  new
ngle  for  preventing  or  treating  NR.
istal atherothrombotic embolization
CI  performed  upon  a  ruptured  plaque  with  thrombus
nd  atherosclerotic  material  leads  to  distal  embolization
f  microthrombi  and  plaque  components  [50].  This  distal
mbolization  is  involved  in  the  NR  phenomenon  [51—53].
istal  microembolization  results  in  an  increase  in  distal
esistance,  multiple  microinfarcts  and  increased  levels  of
yocardial  necrosis  biomarkers,  and  therefore  hampers  the
fﬁcacy  of  PCI  [54,55].  Distal  embolization  is  an  attrac-
ive  component  of  NR  in  terms  of  therapeutic  approach,
nd  has  therefore  been  emphasized  by  some  studies  as  a
ain  contributor  to  NR;  it  is  accessible  to  treatment  with
he  use  of  thrombectomy  catheters.  Nevertheless,  distal
mbolization  is  only  one  of  the  numerous  factors  that  con-
ribute  to  NR  genesis.  NR  was  ﬁrst  described  in  experimental
odels  of  ischaemia  reperfusion  without  any  thrombus  or
istal  embolization.  Also,  Skyschally  et  al.  reported  that
icroembolization  with  microspheres  during  early  reper-
usion  accounted  for  up  to  15%  of  infarct  size  increase,
hich  was  reduced  to  5%  in  case  of  postconditioning  [56].
hus,  focusing  only  on  coronary  microembolization  treat-
ent  to  prevent  the  NR  phenomenon  appears  biased,  andhe  disappointing  results  from  recent  thrombectomy  trials
onﬁrm  the  need  to  consider  alternative  coadjuvant  treat-
ents  and  take  into  account  the  complex  pathophysiology
f  NR  [57,58].
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linical implications of the no-reﬂow
henomenon
R  is  associated  with  larger  infarct  size,  lower  left  ventri-
ular  ejection  fraction,  adverse  left  ventricular  remodelling
n  the  remote  stage  of  myocardial  infarction,  and  increased
ncidences  of  heart  failure,  cardiac  rupture  [22]  and  death,
ompared  with  patients  without  NR  [4,5,10,16,35]. More-
ver,  a  study  using  magnetic  resonance  imaging  showed  that
ersistence  of  microvascular  obstruction  was  a  more  pow-
rful  predictor  of  global  and  regional  functional  recovery
han  transmural  extension  of  infarction  [59]. Thus,  during
hort-term  management,  it  is  not  surprising  that  the  NR
henomenon  correlates  with  an  increased  duration  of  hos-
italization  compared  with  patients  without  NR  [36],  with
conomic  consequences.  Whether  NR  can  affect  the  long-
erm  clinical  prognosis  of  patients  is  an  important  question,
s  it  is  usually  a  transient  phenomenon  that  resolves  over
ime  in  nearly  50%  of  patients.  One  might  hope  that  the
ong-term  consequences  would  be  limited  [14]. NR  has  also
een  found  to  be  an  independent  predictor  of  1-year  mor-
ality,  with  a 3-fold  increase  in  the  adjusted  risk  of  death  in
atients  with  STEMI  undergoing  primary  PCI  [35].  NR  also
redicted  an  increased  risk  of  death  up  to  5  years  after
rimary  PCI  for  STEMI  (Kaplan-Meier  estimates  of  5-year
ortality  of  18.2%  and  9.5%,  respectively;  odds  ratio  2.02,
5%  conﬁdence  interval  1.44—2.82;  P  <  0.001)  [60]. These
ndings  emphasize  that  as  a  major  risk  marker  of  cardiovas-
ular  events,  NR  should  be  identiﬁed  and  treated  as  soon  as
ossible  or,  ideally,  prevented  [7].
o-reﬂow diagnosis
hatever  the  diagnostic  method  used,  one  must  consider
he  dynamic  nature  of  NR  (Table  1).  NR  persists  through-
ut  the  48  hours  after  reperfusion,  although  this  time  frame
s  hypothetical  and  is  based  upon  experimental  ﬁndings
61]. The  severity  of  NR  or  microvascular  obstruction  also
as  consequences  for  its  diagnosis.  A  transient  slowing  of
yocardial  blood  ﬂow  in  the  infarcted  area  will  not  be
ssessed  as  easily  as  a  complete  and  ﬁxed  obstruction  of
he  myocardial  microvasculature.
oronary angiography
oronary  angiography  performed  during  primary  PCI  at  the
cute  phase  of  myocardial  infarction  was  the  ﬁrst  imag-
ng  technique  to  identify  the  NR  phenomenon  in  humans.
n  fact,  the  term  NR  came  naturally  after  the  observation  of
he  absence  of  coronary  ﬂow  despite  correct  implantation
f  a  coronary  stent  or  an  angioplasty  procedure  performed
o  reopen  the  occluded  coronary  vessel.  The  classiﬁcation
f  different  grades  of  angiographic  coronary  blood  ﬂow  has
een  established  according  to  the  Thrombolysis  in  Myocar-
ial  Infarction  (TIMI)  scale  [62].  The  absence  of  reﬂow  is
lassiﬁed  according  to  the  TIMI  angiographic  scale  as  a  grade 1  in  the  culprit  coronary  artery  after  the  PCI  procedure
62]. Coronary  angiography  TIMI  ﬂow  is  simple,  but  this
ethod  lacks  sensitivity  and  speciﬁcity  for  the  assessment
f  NR.  Indeed,  capillary  blood  ﬂow  is  not  measured  directly
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Table  1  Prevalence  of  no-reﬂow/microvascular  obstruction  in  ST-segment  elevation  myocardial  infarction  patient  stud-
ies  with  varying  diagnostic  techniques.
First  author  Population  (n)  Duration  of
ischaemia
(hours)
Reperfusion
strategy
Diagnostic  method  NR  prevalencea
(%)
Santoro  [11]  37  <12  PPCI  with
ﬁnal  TIMI
ﬂow  =  3
ST-segment  regression  <  50%
at  30  minutes
post-reperfusion
43
Morishima  [3] 120  <6  PPCI  TIMI  score  <  2 25
Henriques  [12]  924  —  PPCI  with
ﬁnal  TIMI
ﬂow  =  3
MBG score  <  2  11
Hamada  [13]  104  <6  PPCI  with
ﬁnal  TIMI
ﬂow  =  3
Corrected  TIMI  frame  count  42
Galiuto  [14]  24  <6  PPCI  or
thrombolysis
Transthoracic
echocardiography  with
intravenous  contrast
injection
66
Ito  [15]  126  <24  PPCI  or
thrombolysis
Transthoracic
echocardiography  with
intracoronary  contrast
injection
37
Wu  [16]  44  <24  PPCI  or
thrombolysis
First-pass  perfusion  ce-CMR
(persistent  hyposignal
1—2  minutes  after  gadolinium
injection)
25
Taylor  [17]  20  <12  PPCI  First-pass  perfusion  ce-CMR
(T50%max  delay  >  1  second)
95
Eitel  [18]  738  <12  PPCI  or
thrombolysis
Late  ce-CMR  (persistent
hyposignal  at  10  minutes  on
delayed  enhancement  image)
42
Hombach  [19] 110  <12  PPCI  or
thrombolysis
Late  ce-CMR  (persistent
hyposignal  at  10  minutes  on
delayed  enhancement  image)
46
Mewton  [84]  50  <12  PPCI  or
rescue  PPCI
Early  and  late  ce-CMR
(persistent  hyposignal  at  3
and  10  minutes  on  delayed
enhancement  image)
80  (early);  75
(late)
ce-CMR: contrast-enhanced cardiac magnetic resonance; MBG: myocardial blush grade; PPCI: primary percutaneous coronary
intervention; T50%max: time to 50% maximum myocardial signal intensity: thrombolysis in myocardial infarction.
a The prevalence of no-reﬂow varies widely from 11 to 95%; this can be explained by the different diagnostic tools with various degrees
of sensitivity and speciﬁcity, but also other factors such as time from reperfusion to diagnosis and reperfusion quality.
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aby  angiography,  and  a  signiﬁcant  proportion  of  TIMI  grade  3
ﬂow  patients  actually  present  NR  [12,63].
Myocardial  blush  grade  (MBG)  is  another  imaging  tech-
nique  for  assessing  myocardial  microvasculature  and  tissue
reﬂow  by  angiography  [64].  With  this  method,  angiogra-
phers  assess  the  myocardial  tissue  opaciﬁcation  intensity
with  longer  angiographic  runs,  performed  until  the  venous
phase  of  contrast  passage.  According  to  visual  or  comput-
erized  signal  intensity  automatic  assessment,  myocardial
‘‘blush’’  is  graded  according  to  a  scale  with  four  inten-
sity  grades:  0,  no  myocardial  blush;  1,  minimal  myocardial
blush  or  contrast  density;  2,  moderate  myocardial  blush
or  contrast  density,  but  less  than  that  obtained  during
angiography  of  a  contralateral  non-infarct-related  coronary
c
r
l
srtery;  and  3,  normal  myocardial  blush  or  contrast  density,
imilar  to  that  obtained  during  angiography  of  a contralat-
ral  non-infarct-related  coronary  artery.  However,  this  very
ow  contrast-to-noise  imaging  method  of  myocardial  tissue
paciﬁcation  suffers  from  the  same  limitations  as  the  angi-
graphic  TIMI  scale  [65]. The  timing  of  angiography  is  too
arly  to  assess  all  the  reperfusion  injuries  and  other  com-
lex  phenomena  that  develop  in  the  hours  and  days  after
eperfusion.  This  is  one  reason  why  post-PCI  TIMI  ﬂow  or  MBG
re  not  necessarily  predictive  of  the  presence  of  microvas-
ular  obstruction  (MVO)  as  detected  by  cardiac  magnetic
esonance  (CMR)  [65,66]. Indeed,  whereas  at  a  population
evel,  a  grade  3  MBG  or  TIMI  ﬂow  indicates  a good  progno-
is,  on  an  individual  basis,  up  to  60%  of  STEMI  patients  with
666  C.  Bouleti  et  al.
Figure 2. Myocardial tissue characterization and cardiac magnetic resonance (CMR) techniques to assess microvascular obstruction with
contrast-enhanced CMR. Mid-ventricular short-axis views in an anterior STEMI patient with optimal reperfusion on CMR performed 48 hours
after admission. A. T2-weighted (T2W) acquisition showing transmural extensive oedema in the anteroseptal wall (arrow). B. First-pass
perfusion acquisition, at the same time as gadolinium intravenous bolus, where the hypoperfused area appears hypointense (red contour) in
the subendocardium of the anteroseptal wall. C & D. Subsequent delayed enhancement views, performed (C) 3 minutes and (D) 10 minutes
after gadolinium administration. The microvascular obstruction area on these views is hypointense (red contour); on the 10-minute acqui-
sition it is surrounded by hyperintense myocardium that corresponds to the myocardial infarcted tissue. As gadolinium passively and slowly
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ptimal  angiographic  reperfusion  indices  (MBG  and  TIMI
ow  =  3)  show  NR  on  a  CMR  image  acquired  in  the  following
2  hours  [67].
ardiac magnetic resonance imaging
MR  imaging  with  gadolinium  administration  is  the  gold-
tandard  non-invasive  technique  for  assessing  MVO  with  the
ighest  spatial  resolution  and  good  levels  of  reproducibil-
ty  [68].  The  diagnosis  of  NR  by  contrast-enhanced  CMR
ce-CMR)  is  based  on  the  speciﬁc  characteristics  of  myocar-
ial  capillary  circulation  within  the  injured  myocardium,
ompared  with  the  healthy  myocardium.  The  extracellular
ontrast  agent  (gadolinium  chelate),  injected  intravenously,
irculates  and  is  distributed  differently  according  to  the
oronary  microcirculation  state.  The  differences  in  myocar-
ial  tissue  concentration  of  gadolinium  at  the  time  of
MR  image  acquisition  allow  the  classiﬁcation  of  myocar-
ial  tissue  as  normal  or  infarcted  with  or  without  MVO
69].  The  addition  of  pre-contrast  T2  weighted  sequences
rovides  signiﬁcant  information  about  myocardial  oedema
nd  intramyocardial  haemorrhage  [70,71].  CMR  has  also
een  validated  against  pathology  in  experimental  models  of
schaemia-reperfusion  [61,72].
There  are  two  distinct  approaches  to  diagnosing  MVO  by
e-CMR  (also  presented  in  Fig.  2):  the  perfusional  approach
nd  the  delayed  enhancement  approach.
erfusional approach
he  initial  description  of  NR  by  ce-CMR  was  based  upon
he  ﬁrst-pass  perfusion  method  in  experimental  models  and
TEMI  patients  [16,61,72].  The  NR  area  is  composed  of
njured  myocardium  where  the  microvasculature  is  severely
amaged  or  destroyed;  this  results  in  the  absence  of  or
igniﬁcant  delay  in  the  appearance  of  gadolinium  within
his  area,  and  therefore  a  subsequent  hypoenhancement
Fig.  2B)  within  the  core  of  the  infarct,  compared  with  other
egions  of  the  myocardium  with  normal  microvascular  archi-
ecture.  MVO  is  characterized  by  low  signal  intensity  early
fter  contrast  injection  followed  by  a  very  slow  or  no  growth
f  signal  intensity.  Some  authors  proposed  setting  the  time
or  this  hypointensity  assessment  at  >  1  minute  after  contrast
t
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Tinute microvascular obstruction area (D) is roughly half the size of
olus  [72]  or  as  myocardial  regions  with  a  delay  of  >  1  second
o  reach  the  time  to  50%  maximum  signal  intensity  (T50%max)
or  the  non-infarcted  myocardium  [17]. However,  these  arbi-
rary  thresholds  are  rarely  used  in  clinical  practice.
With  the  technological  progress  made  in  perfusional
equences,  a  signiﬁcant  proportion  of  STEMI  patients  (>50%)
ave  a  hypointense  area  on  ﬁrst-pass  perfusion  images.  This
ypointensity  relates  to  the  presence  of  NR,  but  also  to  the
lowing  of  contrast  media  in  the  reperfused  myocardium
oedema)  on  the  ﬁrst-pass  perfusion  acquisitions.  How-
ver,  on  the  10-minute  contrast-enhanced  sequences,  this
ypointense  area  may  disappear.  This  shows  the  good  sen-
itivity  of  ﬁrst-pass  perfusion  sequences,  but  their  lower
peciﬁcity  [67].
elayed enhancement approach
s  shown  in  Fig.  2C  and  Fig.  2D,  the  NR  zone  is  deﬁned
s  the  hypointense  area  within  the  core  of  the  myocar-
ial  infarct  on  delayed  enhancement  sequences  performed
t  3  minutes  (early  contrast  enhancement)  or  10  minutes
late  contrast  enhancement)  following  a gadolinium  intra-
enous  (IV)  bolus.  Delayed  enhancement  sequences  offer
he  advantage  of  better  spatial  resolution  and  complete
eft  ventricular  coverage  compared  with  ﬁrst-pass  per-
usion  sequences.  The  hypointense  myocardial  area  on  these
equences  corresponds  to  severely  obstructed  myocardium
hat  the  extracellular  media  did  not  reach,  even  after
0  minutes  of  passive  diffusion.  The  other  myocardial
egions  (hypointense  on  the  ﬁrst-pass  perfusion  sequences),
here  contrast  perfusion  and  diffusion  persist,  correspond
o  areas  of  ‘‘slow-ﬂow’’  or  ‘‘low-reﬂow’’.  The  progressive
ignal  intensity  growth  within  the  NR  area  between  the  early
nd  late  acquisitions  is  related  to  the  passive  diffusion  of  the
ontrast  media  within  the  severely  injured  myocardium  and
xtracellular  space  (Fig.  3).
There  are  currently  no  guidelines  for  the  best  timing  or
ype  of  sequence  to  assess  MVO/NR  by  ce-CMR.  Various  CMR
equences  have  been  used,  with  signiﬁcant  differences  in
erms  of  results  and  clinical  relevance.  However,  the  late
adolinium  enhancement  approach  at  10  minutes  appears  to
e  the  most  reliable  and  relevant  method  to  assess  MVO.
he  persistence  of  a  microvascular  area  where  gadolinium
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Figure 3. Short-axis view of early and late contrast-enhanced cardiac magnetic resonance imaging in a patient with acute reperfused
lateral myocardial infarction. The infarcted myocardium appears hyperintense on the late enhancement image, with a subendocardial
area with persistent low signal intensity (black arrow) corresponding to severe microvascular obstruction (right panel). On the early late
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obstruction area already appears hypointense (black arrow).
does  not  penetrate  after  10  minutes  is  a  marker  of  more
severe  injury.  Also,  late  gadolinium  enhancement  sequences
are  robust  and  can  be  acquired  in  one  breath  hold,  covering
the  whole  ventricle  with  high  spatial  resolution  [73]. Finally,
recent  papers  have  compared  the  respective  predictive
values  of  MVO  deﬁned  by  the  ﬁrst-pass  perfusion  tech-
nique  versus  late  gadolinium  enhancement  technique  (at
10  minutes)  for  adverse  cardiovascular  events,  and  results
the  late  enhancement  gadolinium  technique  was  a  better
predictor  [67].  Recent  papers  in  large  cohorts  of  patients
where  MVO  was  assessed  with  the  late-enhancement  tech-
nique  at  10  minutes  have  shown  the  independent  predictive
value  of  MVO  on  subsequent  major  cardiac  events  [18,74].
Of  note,  CMR,  with  its  powerful  tissue  characterization
properties,  also  enables  the  assessment  of  important  fac-
tors  of  ischaemia-reperfusion  injury  that  participate  in  the
ﬁnal  MVO,  such  as  oedema,  haemorrhage  and  inﬂammation
[70,71,75—77].  The  development  and  use  of  these  imaging
abilities  in  future  studies  may  be  important  for  understand-
ing  MVO  and  treating  it  more  efﬁciently.
Other techniques
Other  diagnostic  techniques  have  been  used  to  assess  NR,
such  as  the  post-reperfusion  electrocardiogram  [66],  con-
trast  echocardiography  [3]  and  nuclear  imaging,  but  their
lack  of  sensitivity,  their  complexity  and  limited  accessibility
make  these  techniques  less  attractive  for  NR  assessment  in
routine  clinical  practice.
No-reﬂow treatment
NR  is  a  phenomenon  that  has  been  known  for  40  years,
but  in  this  time  very  little  progress  has  been  made  in
terms  of  therapies  directed  towards  the  microcirculation
[78,79].  There  are,  in  fact,  no  speciﬁc  therapies  target-
ing  NR  that  are  applicable  and  recommended  for  the
routine  management  of  STEMI  patients.  Although  there  are
a  lot  of  experimental  data  showing  the  signiﬁcant  positive
i
f
s
nardium is still saturated with gadolinium, but the microvascular
ffect  of  treatments  applied  before  and  after  reperfusion  in
schaemia-reperfusion  models,  these  treatments  have  failed
o  show  any  positive  effect  in  human  patients  [10,80].  How-
ver,  some  strategies  for  NR  treatment  have  shown  effects
hat  are  at  least  controversial  and  at  best  beneﬁcial.  In  the
ollowing  paragraphs,  we  will  focus  speciﬁcally  upon  treat-
ents  that  are  readily  available  in  routine  clinical  practice,
ut  have  to  be  used  off-label  for  the  NR  indication,  and
reatments  that  are  currently  being  assessed  in  phase  III
rials,  which  appear  promising.
on-pharmacological approach
echanical ischaemic postconditioning
n  2003,  Zhao  et  al.  showed  in  an  experimental  model
f  ischaemia-reperfusion  that  brief  episodes  of  ischaemia-
eperfusion  performed  immediately  after  reﬂow  following
rolonged  ischaemia  signiﬁcantly  reduced  the  ﬁnal  infarct
ize  by  40%  [81].  In  addition,  this  group  showed  that  mechan-
cal  postconditioning  also  signiﬁcantly  reduced  myocardial
edema  and  many  other  cytotoxic  reactions  within  the
yocardial  microvasculature  following  reperfusion  [82].
hese  results  were  translated  to  STEMI  patients  in  2005  by
taat  et  al.  [83]. In  this  proof-of-concept  trial,  ischaemic
ostconditioning  was  applied  within  1  minute  after  reﬂow  by
nﬂating/deﬂating  the  angioplasty  balloon  upstream  of  the
ulprit  lesion  in  four  successive  1-minute  cycles.  This  strat-
gy  signiﬁcantly  reduced  infarct  size  by  36%,  as  assessed
y  the  creatine  kinase  area  under  the  curve  release.  In
nother  trial,  Mewton  et  al.  showed  that  ischaemic  post-
onditioning  signiﬁcantly  reduced  MVO  by  around  50%,  as
ssessed  by  ce-CMR  at  72  hours,  thus  suggesting  a  speciﬁc
ffect  of  ischaemic  postconditioning  on  NR  [84].  However,
ecent  trials  in  larger  groups  of  STEMI  patients  have  failed  to
how  any  signiﬁcant  beneﬁt  of  this  technique  [85,86].  Even
f  the  meta-analysis  of  all  postconditioning  trials  shows  a
avourable  effect  of  ischaemic  postconditioning  on  infarct
ize  surrogates  [87], stronger  evidence  from  phase  III  trials
eeds  to  be  provided  for  this  technique  to  be  recommended
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or  the  management  of  STEMI  patients.  The  ongoing  DANAMI-
 trial  (Danish  Study  of  Optimal  Acute  Treatment  of  Patients
ith  ST-elevation  Myocardial  Infarction-3;  ClinicalTrials.gov
dentiﬁer  NCT01435408)  will  assess  the  effect  of  three
ifferent  reperfusion  protocols,  including  ischaemic  post-
onditioning,  on  clinical  outcomes  (all-cause  death  and
eart  failure)  at  2  years  in  2000  STEMI  patients.  Poten-
ial  therapies  such  as  ischaemic  preconditioning  and  remote
schaemic  preconditioning  have  shown  beneﬁt  in  reducing
R  and  clinical  variables  [88].  A  recent  systematic  review
nd  meta-analysis  showed  that  remote  ischaemic  precon-
itioning  appears  to  be  an  effective  method  for  reducing
schaemia-reperfusion  myocardial  injury,  and  suggests  that
t  may  reduce  long-term  clinical  events  [88]. Nevertheless,
his  strategy  has  not  yet  been  deployed  in  the  clinical  setting
o  reduce  NR  [89].
truggles against distal coronary embolization
hrombus  aspiration  or  distal  ﬁlters  have  been  developed  to
educe  the  risk  of  distal  embolization  involved  in  MVO  patho-
enesis.  Several  studies  have  demonstrated  that  thrombus
spiration  before  PCI  is  associated  with  an  improvement  in
linical  outcomes  in  patients  with  STEMI  [90—93].  However,
 recent  multicentre  randomized  trial  demonstrated  that
outine  thrombus  aspiration  before  PCI  compared  with  PCI
lone  did  not  reduce  30-day  mortality  among  patients  with
TEMI  [57].  Another  mechanical  approach  consists  of  deploy-
ent  of  distal  embolic  protection  devices  before  stenting.
lthough  this  system  effectively  retrieved  embolic  debris
94],  it  failed  to  improve  microvascular  ﬂow,  infarct  size  or
linical  outcome  [94—96].  Finally,  the  mini-invasive  strategy
onsisting  of  delayed  stenting  after  reperfusion  and  several
ays  of  antithrombotic  treatment  may,  in  theory,  limit  the
eared  distal  embolization  when  the  stent  is  deployed,  but
ts  efﬁcacy  has  yet  to  be  proven  in  terms  of  mortality  or
nfarct  size  reduction.
Thus,  distal  embolization  plays  a  role  in  NR,  but  its
nvolvement  seems,  in  fact,  quite  limited  [56];  this  might
xplain  the  recent  disappointing  results  of  published  tri-
ls  focusing  only  on  this  variable  for  the  prevention  of
R.  Prevention  of  microvessel  coronary  embolization  should
robably  be  integrated  into  a  global  approach  with  coadju-
ant  treatments  to  take  into  account  the  other  contributors
o  NR  pathogenesis.  During  the  past  10  years,  many  phase
I  clinical  trials  have  been  performed  to  ﬁnd  coadjuvant
harmacological  interventions  to  improve  the  myocardial
amage  associated  with  STEMI.
harmacological therapies
etoprolol
reclinical  results  from  a  pig  model  of  myocardial  infarction
howed  that  IV  metoprolol  administered  before  reperfusion
igniﬁcantly  reduced  infarct  size  [97,98].  The  underlying
echanism  for  this  infarct  size  reduction  may  be  linked  to
 reduction  in  reperfusion  injury  caused  by  the  effect  of
etoprolol  on  circulating  neutrophils  and  platelets.
The  METOCARD-CNIC  trial  (Effect  of  Metoprolol  in  Cardio-
rotection  During  an  Acute  Myocardial  Infarction)  showed
hat  IV  metoprolol  administered  before  reperfusion  signif-
cantly  decreased  infarct  size  assessed  by  CMR  in  anterior
b
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TEMI  patients  compared  with  placebo  [99].  Moreover,  the
V  metoprolol  group  had  a signiﬁcantly  higher  left  ventri-
ular  ejection  fraction  at  6-month  follow-up  [100].  These
esults  are  very  promising,  as  the  use  of  IV  beta-blockers
rior  to  reperfusion  [99]  is  a  readily  accessible  form  of  treat-
ent  in  routine  clinical  practice.  However,  the  COMMIT  trial
ClOpidogrel  and  Metoprolol  in  Myocardial  Infarction
rial)  failed  to  show  any  effect  of  metoprolol  on  mortal-
ty  [101],  although  the  study  design  may  have  contributed
o  this  ﬁnding  [101].
Other  randomized  trials  are  necessary  to  prove  whether
V  metoprolol  does  indeed  have  beneﬁcial  effects  on
schaemia-reperfusion  lesions  [102],  and  whether  these
ffects  may  translate  into  clinical  beneﬁt.
denosine
ctivation  of  the  adenosine  triphosphate  (ATP)-sensitive
otassium  channels  inside  mitochondria  prevents  mitochon-
rial  calcium  overload  and  cytochrome  c  release,  thus
voiding  mitochondrial  permeability  transition  pore  open-
ng,  which  precludes  cell  apoptosis  [103,104].  Adenosine-
nduced  opening  of  ATP-sensitive  potassium  channels  thus
xplains,  at  least  in  part,  the  mechanism  by  which  adenosine
ay  elicit  cardioprotection.
After  promising  results  from  small  randomized  studies
105,106],  large  randomized  trials  have  reported  only  poten-
ial  beneﬁcial  effects  but  not  deﬁnitive  results  [107,108].
inally,  the  Acute  Myocardial  Infarction  Study  of  Adenosine
I  (AMISTAD-II),  speciﬁcally  designed  to  investigate  the  role
f  adenosine  in  STEMI,  found  no  difference  in  the  primary
ndpoint  of  new  congestive  heart  failure,  re-hospitalization
or  congestive  heart  failure  or  death  from  any  cause  at  6
onths  [109].  In  a  post  hoc  analysis,  in  patients  receiving
eperfusion  therapy  within  3  hours  of  symptoms,  adenosine
educed  1-month  and  6-month  mortality  rates,  but  these
esults  have  to  be  interpreted  with  caution  [110]. In  the
ost  recent  trials,  adenosine  was  administered  by  intracoro-
ary  injection  at  high  doses,  and  was  not  associated  with
ncreased  myocardial  salvage  assessed  by  CMR  [111,112]. So,
lthough  adenosine  has  been  evaluated  in  several  trials,  we
till  do  not  have  deﬁnite  proof  of  efﬁcacy  on  NR,  infarct  size
r  clinical  prognosis.
asodilators (verapamil, nitroprusside,
icardipine)
asodilators  are  supposed  to  improve  microvascular  dysfunc-
ion  by  preventing  microvessel  spasm  and  regulating  their
ndothelial  function;  results,  however,  are  highly  contro-
ersial.
Rezkalla  et  al.  studied  the  efﬁcacy  of  nitroprusside,
icardipine  and  verapamil  after  primary  PCI,  and  showed  an
ncrease  in  TIMI  ﬂow  grade  and  MBG  score  [113].  A  recent
eta-analysis  showed  that  intracoronary  verapamil  injec-
ion  reduced  the  2-month  rate  of  major  adverse  events  in
atients  who  underwent  PCI  [114].  However,  in  a  double-
lind  randomized  trial,  intracoronary  administration  of
itroprusside  before  primary  PCI  failed  to  improve  coro-
ary  ﬂow  and  myocardial  tissue  reperfusion  compared  with
lacebo  [115].
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In  summary,  vasodilators  appear  to  have,  at  best,  a
limited  effect  on  NR,  and  the  clinical  signiﬁcance  of  these
ﬁndings  is  unclear.
Glycoprotein IIb/IIIa inhibitors
Glycoprotein  IIb/IIIa  inhibitors  were  developed  to  reduce
thrombotic  events  because  of  their  potent  effect  on  platelet
aggregation  and  vascular  clotting.  In  a  small  phase  II  study
in  STEMI  patients  treated  with  thrombolysis  combined  with
abciximab,  Zoni  et  al.  showed  that  abciximab  signiﬁcantly
reduced  infarct  size  and  MVO  size,  as  determined  by  CMR
[116].  These  ﬁndings  conﬁrm  the  role  of  in  situ  microvascular
thrombosis  with  platelets  and  platelet-leukocyte  aggregates
in  the  pathogenesis  of  NR.  More  recently,  the  INFUSE-AMI
trial  performed  in  452  anterior  STEMI  patients  undergoing
PCI  showed  that  intracoronary  administration  of  abciximab
signiﬁcantly  reduced  infarct  size  at  30  days,  as  determined
by  CMR  [117].  Abciximab  and  other  antiplatelet  agents  [118]
seem  to  have  a  signiﬁcant  cardioprotective  effect,  which
might  be  mediated  through  their  inhibition  of  the  explo-
sive  platelet  activation  following  myocardial  infarction.
However,  this  speciﬁc  beneﬁt  is  counterbalanced  by  their
induction  of  bleeding  events.  The  current  standard  of  care
for  STEMI  patients  already  includes  potent  oral  antiplatelet
agents,  and  glycoprotein  IIb/IIIa  inhibitors  are  only  recom-
mended  for  their  speciﬁc  antithrombotic  effect  in  selected
STEMI  patients  [119].
Cyclosporine A
Cyclosporine  A  is  a  potent  inhibitor  of  the  mitochondrial
permeable  transition  pore.  Cyclosporine  A  prevents  the
mitochondria,  the  energy  power-plants  of  all  myocardial
cells,  from  opening  and  being  destroyed  after  the  vari-
ous  intracellular  stimuli  triggered  by  the  brutal  reperfusion
of  the  ischaemic  myocardium  [120,121].  The  mitochondria
appear  to  play  a  central  role  in  the  various  mechanisms
involved  in  reperfusion  injury  and  NR;  they  are  therefore
important  therapeutic  targets  for  therapies  aimed  at  reduc-
ing  NR.  After  validation  in  several  experimental  models,  Piot
et  al.  showed  that  a  single  bolus  of  cyclosporine  A  admin-
istered  immediately  before  PCI  signiﬁcantly  reduced  infarct
size  in  STEMI  patients  compared  with  placebo  [122]. This
study  did  not  show  a  signiﬁcant  effect  on  NR,  which  was  not
assessed.  However  very  recent  results  in  a  porcine  model
of  ischaemia-reperfusion  have  shown  a  signiﬁcant  effect  of
cyclosporine  on  MVO  and  microcirculation  [123]. Deﬁnitive
proof  for  or  against  cyclosporine  use  in  STEMI  patients  will
soon  be  available  after  publication  of  the  results  from  the
ongoing  phase  III  CIRCUS  trial  [124].
Beyond  cardiomyocytes,  only  a  few  studies  have  focused
on  vessel  treatment  to  prevent  the  NR  phenomenon,  which
remains,  after  all,  a  vascular  problem  involving  the  car-
diomyocytes,  and  not  the  other  way  around.
Vascular signalling pathways and future
research avenuesThe  loss  of  vascular  integrity,  with  destroyed  tight  and
adherens  junctions  leading  to  increased  vascular  perme-
ability,  plays  a  key  role  in  NR  pathogenesis  (Fig.  1).  It  is
v
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andatory  to  better  understand  the  pathophysiology  and
ignalling  pathways  involved  in  the  loss  of  microvascular
ntegrity  to  propose  therapeutic  strategies  targeting  the
icrovasculature  itself.  Pannitteri  et  al.  showed  that  there
ere  two  waves  of  release  of  angiogenic  factors  during  AMI
n  humans;  they  provided  evidence  for  an  early  peak  of  VEGF
at  24  hours)  and  a  late  peak  of  VEGF  (at  approximately
70  hours)  [125].  Whereas  the  late  peak  seems  to  support
eneﬁcial  angiogenesis  (with  simultaneous  angiopoietin-
 release,  which  is  necessary  for  efﬁcient  angiogenesis,
ogether  with  VEGF),  the  early  peak  was  associated  with
roinﬂammatory  cytokines,  such  as  interleukin-6  and  trans-
orming  growth  factor-beta,  suggesting  a  deleterious  effect.
e  can  thus  hypothesize  that  the  early  VEGF  release  after
MI  will  lead  to  the  endothelial  junction  destabilization
nd  vascular  permeability  that  is  part  of  the  NR  pathogen-
sis,  whereas  the  delayed  phase  could  promote  reactive
ngiogenesis.  It  would  thus  be  interesting  to  counteract
EGF-induced  vascular  permeability  in  the  acute  phase  of
MI,  without  impairing  delayed  angiogenesis.
We  recently  showed  that  angiopoietin-like  4  (ANGPTL4)
ounteracted  early  ischaemia-induced  VEGF  signalling  and
isruption  of  endothelial  cell  junctions,  thereby  leading  to
ubsequent  protection  of  the  coronary  capillary  network
nd  reduction  of  infarct  size  [126]. These  data  showed  that
NGPTL4  might  be  a  relevant  target  for  therapeutic  vas-
uloprotection,  thus  being  crucial  for  preventing  NR  and
onferring  secondary  cardioprotection  during  AMI  [126,127].
e  also  showed  that  ANGPTL4  had  protective  effects  on
he  cerebrovascular  and  functional  damage  after  ischaemic
troke  that  shares  some  pathophysiological  factors  with
MI  [127]. ANGPTL4  would  counteract  the  loss  of  vascu-
ar  integrity  in  ischaemic  stroke  by  restricting  Src  kinase
ignalling  downstream  from  VEGF  receptor  2.  These  results
uggest  that  ANGPTL4  is  a  regulator  of  endothelial  barrier
ntegrity  during  cardiovascular  ischaemic  diseases  [128],  and
ight  be  a relevant  target  for  NR  prevention.  Recently,  we
onﬁrmed  the  involvement  of  ANGPTL4  in  NR  pathogenesis,
ith  lower  ANGPTL4  serum  concentrations  on  admission  in
TEMI  patients  being  associated  with  CMR-detected  NR  after
eperfusion  [36].
Moreover,  beyond  counteracting  VEGF-induced  VEGF
eceptor  2/VE-cadherin  complex  disruption,  agents  such  as
ngiopoietin-1  [129]  and  ﬁbroblast  growth  factor  [130]  have
een  reported  to  inhibit  VE-cadherin  internalization  and
o  help  with  maintenance  of  vascular  integrity.  In  a  study
y  Sandhu  et  al.,  angiopoietin-1  expression  was  decreased
n  the  infarcted  area  compared  with  control  myocardium
n  a  rat  model  of  AMI  [131],  leading  to  impaired  vas-
ular  integrity.  Fibroblast  growth  factor-2  has  also  been
emonstrated  to  exert  a  cardioprotective  effect  in  a  closed-
hest  model  of  cardiac  ischaemia-reperfusion  injury  [132].
hether  ﬁbroblast  growth  factor-2  acts  predominantly  on
ardiomyocytes  or  also  targets  endothelium  was  not  fully
etermined.  As  angiopoietin-1  and  ﬁbroblast  growth  factor-
 signalling  plays  a  key  role  in  the  maintenance  of  vascular
ntegrity  [132],  they  appear  to  be  potential  targets  for
uture  development  of  vascular  therapeutics  [133]  to  pre-
ent  the  NR  phenomenon.
Ischaemia-reperfusion  injury  also  involves  surface  adhe-
ion  molecules,  such  as  P-selectin,  P-selectin  glycoprotein
igand-1,  Mac-1  and  intercellular  adhesion  molecule-1.  The
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ccumulation  of  red  blood  cells  in  the  interstitium,  caused
y  microvessel  disruption,  results  in  accumulation  of  degra-
ation  products  of  haeme  that  attract  inﬂammatory  cells.
ransmigration  of  leukocytes  through  the  vessel  wall  might
lso  contribute  to  NR.  Proteolytic  enzymes  from  neutrophils
an  be  important  inducers  of  vascular  permeability,  and
ntercellular  adhesion  molecule-1  crosslinking  was  shown
o  trigger  VE-cadherin  phosphorylation,  while  endothelial
itric  oxide  synthase,  Src  and  Rho  guanosine  triphosphatase
ctivation  were  reported  to  be  involved  in  this  signalling
echanism  [134].  Nevertheless,  sites  of  permeability  induc-
ion  can  be  spatially  and  temporally  distinct  [135], and  the
oupled  relationship  between  leucocyte/platelet  activation
nd  microvessel  permeability  should  be  re-evaluated  in  AMI.
Finally,  a  recent  study  showed  that  imatinib  —  a  Food  and
rug  Administration-approved  tyrosine  kinase  inhibitor  —
irectly  protects  the  endothelial  barrier  under  inﬂammatory
onditions  [136].  Imatinib  binds  to  an  intracellular  pocket
ocated  within  tyrosine  kinases,  thereby  inhibiting  ATP  bind-
ng  and  preventing  phosphorylation  and  the  subsequent
ctivation  of  growth  receptors,  such  as  platelet-derived
rowth  factor  receptor,  and  their  downstream  signal  trans-
uction  pathways.  Imatinib  attenuated  vascular  leakage  in  a
urine  model  of  sepsis,  even  when  it  was  initiated  a  consid-
rable  time  after  induction  of  sepsis.  Imatinib  may  thus  be  a
uitable  therapy  for  the  treatment  of  diseases  characterized
y  vascular  leakage,  such  as  the  acute  phase  of  AMI.
onclusion
R  is  a  multifactorial  and  complex  phenomenon,  and  an
ndependent  marker  of  clinical  adverse  outcome  in  STEMI
atients.  The  limited  access  to  performant  diagnostic  tools,
s  well  as  its  dynamic  nature  in  intensity  and  time  restrict
he  therapeutic  window  in  routine  clinical  practice  for
TEMI  patients.  There  is  currently  no  efﬁcient  therapy
gainst  myocardial  haemorrhage,  oedema  and  NR  [137].
everal  clinical  studies  are  underway  and  are  encouraging.
 promising  therapeutic  target  seems  to  be  the  coro-
ary  endothelium,  which  plays  a  central  role  in  NR.  The
ndothelial  barrier  involvement  in  NR,  demonstrated  in
xperimental  in  vitro  and  in  vivo  studies,  might  offer  an
riginal  new  avenue  for  clinical  research  in  AMI  patients.
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